In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National Kidney Foundation 2021 Spring Clinical […]readmore
Tags : Lupkynis
Shots: The AURORA 2 involves assessing Lupkynis vs control arm in 216 patients who have completed P-III AURORA 1 study for 1 year Results: reduction in UPCR from pre-treatment baseline […]readmore
Shots: The P-III AURORA 1 study involves assessing the efficacy and safety of Lupkynis (23.7mg, bid) + MMF and low-dose corticosteroids vs MMF and low-dose corticosteroids alone in 357 adults […]readmore